Ratings by Credit Suisse (Brad Canino)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
4/7/2021 Affimed Therapeutics AFMD Maintain Outperform
(N/A)
 
 
  Details
3/31/2021 Deciphera DCPH New Coverage Outperform
(N/A)
40.40
(34.60)
-14.36% Details
3/31/2021 Blueprint Medicines BPMC New Coverage Neutral
(N/A)
92.01
(102.29)
11.17% Details
3/31/2021 Exelixis EXEL New Coverage Outperform
(N/A)
22.08
(21.40)
-3.08% Details
3/31/2021 Epizyme EPZM New Coverage Outperform
(N/A)
7.45
(4.55)
-38.93% Details
3/31/2021 Zymeworks ZYME New Coverage Outperform
(N/A)
29.83
(23.00)
-22.9% Details
3/31/2021 Affimed Therapeutics AFMD New Coverage Outperform
(N/A)
7.32
(5.99)
-18.17% Details
3/31/2021 Mersana MRSN New Coverage Neutral
(N/A)
15.97
(8.45)
-47.09% Details
3/31/2021 Seagen SGEN New Coverage Neutral
(N/A)
139.93
(171.43)
22.51% Details